Vaccinia virus-sensitive tumor cells

Vaccinia virus-sensitive tumor cells are malignant cells characterized by specific molecular vulnerabilities that allow for selective infection and destruction by oncolytic vaccinia viruses (PMID: 21451545). These cells often exhibit deficiencies in the type I interferon (IFN) signaling pathway, which normally serves as a primary defense against viral infection in healthy cells (Nature Reviews Cancer, 2011). Additionally, the high metabolic rate and elevated levels of thymidine kinase in these tumor cells support rapid viral replication, as the virus relies on the host cell's nucleotide pool (Journal of Virology, 2006). Many sensitive cells also overexpress the epidermal growth factor receptor (EGFR), which can facilitate viral entry and activation of the Ras/MAPK pathway, further promoting viral protein synthesis (Molecular Therapy, 2015). Therapeutic agents like Pexastimogene devacirepvec (Pexa-Vec) are engineered to exploit these characteristics, ensuring that viral replication is restricted to the tumor microenvironment (NIH, ClinicalTrials.gov). Upon infection, the virus induces direct oncolysis, causing the tumor cell to burst and release progeny viruses along with tumor-associated antigens. This process transforms the immunosuppressive tumor microenvironment into an inflamed state, recruiting T-cells and other immune effectors to attack both the infected and uninfected tumor cells (PubMed, PMID: 28934444). Consequently, these cells serve as the primary site for both direct viral therapy and the initiation of a broader systemic anti-cancer immune response.

Other names

Oncolytic vaccinia virus-susceptible cellsVV-sensitive cancer cellsVaccinia-susceptible tumor cellsOncolytic virus-sensitive tumor cells

Oncolytic viruses like Vaccinia virus selectively infect and replicate within tumor cells, leading to direct cell lysis (oncolysis) and the release of tumor-associated antigens and cytokines (e.g., GM-CSF), which stimulate a systemic anti-tumor immune response (PMID: 21451545).